Everything below concerns LC-MS/MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a metabolic modulator. |
| Approved medical use | None in major jurisdictions | Not a registered drug. |
| Common test matrix | Urine | Most anti-doping samples use urine. |
| Typical detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Reference standard storage | -20 °C, desiccated | Typical for analytical standards. |
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
South Beach challenged rival AriZona in sales and was pursuing Snapple for leadership in the new age drink category. Less than pleased, rival AriZona slapped the company with a lawsuit claiming that SoBe had copied its bottle design or stolen trade secrets. Then Judge Sonia Sotomayor ruled in SoBe's favor denying a preliminary injunction. Legal action proceeded and persisted on the federal and state level until 2007, long after the company had been sold to PepsiCo. In 2007, the court dismissed all AriZona claims on summary judgement In 2001, Bello was named Ernst and Young's National Entrepreneur of the Year in the Consumer Products category for his accomplishments at SoBe.
Noriega's relationship with the U.S. deteriorated further during the late 1980s, particularly after the U.S. began to suspect that Noriega was supporting other intelligence services. Hersh wrote in 1986 that U.S. intelligence officials suspected that Noriega was selling intelligence to the Cuban government of Fidel Castro; his report received widespread attention. Bob Woodward published a story about Noriega in The Washington Post soon afterward, going into even greater detail about Noriega's intelligence connections. Woodward and Hersh's reputations made certain that the stories were taken seriously. Spadafora had also informed the U.S. Drug Enforcement Administration (DEA) of some of his findings about Noriega's involvement in drug smuggling. Multiple U.S. agencies continued to investigate Noriega despite opposition from the Reagan administration. In 1988 Noriega was indicted by U.S. federal grand juries in courts in Miami and Tampa on charges of drug-trafficking. The indictment accused him of "turning Panama into a shipping platform for South American cocaine that was destined for the U.S., and allowing drug proceeds to be hidden in Panamanian banks". Soon afterward an army colonel and a few soldiers made an attempt to overthrow Noriega; their poorly planned effort was crushed within a day. The presidential election of May 1989 was marred by fraud and violence. Coalición para la Liberación Nacional (Coalition for National Liberation), a pro-military coalition led by the PRD, named Carlos Duque, a former business partner of Noriega, as its candidate.
=== Clinical research === The therapeutic effects of bromantane in asthenia are said to onset within 1–3 days. It has been proposed that the combination of stimulant and anxiolytic activity may give bromantane special efficacy in the treatment of asthenia. In a large-scale, multi-center clinical trial of 728 patients diagnosed with asthenia in Russia, bromantane was given for 28 days at a daily dose of 50 mg or 100 mg. The study concluded with an impression score of 76.0% on the CGI-S and 90.8% on the CGI-I for bromantane, indicating that it is broadly applicable and highly effective. The therapeutic benefit against asthenia was observed to still be present one month after discontinuation of the drug. 3% of patients experienced side effects; though none were considered serious; and 0.8% of patients discontinued treatment due to side effects. Bromantane was also noted to normalize the sleep–wake cycle.
Endocrine: Impotence, increased or decreased libido: gynecomastia in the male; breast enlargement and galactorrhea in the female; testicular swelling; elevation or depression of blood sugar levels. Other: Jaundice (simulating obstructive); altered liver function; parotid swelling; alopecia; flushing; weight gain or loss; urinary frequency, nocturia; perspiration.
However, the experimental chemistry of meitnerium has not received as much attention as that of the heavier elements from copernicium to livermorium. Lawrence Berkeley National Laboratory tried to synthesize 271Mt in 2002–2003 for a possible chemical investigation of meitnerium, as it was expected that it might be more stable than nearby isotopes due to having 162 neutrons, a magic number for deformed nuclei; its half-life was predicted to be a few seconds, long enough for a chemical investigation. However, no atoms of 271Mt were detected; this isotope of meitnerium is currently unknown. An experiment determining the chemical properties of a transactinide would need to compare a compound of that transactinide with analogous compounds of some of its lighter homologs: for example, in the chemical characterization of hassium, hassium tetroxide HsO4 was compared with the osmium analog, osmium tetroxide OsO4. In a preliminary step toward determining the chemical properties of meitnerium, the GSI attempted sublimation of rhodium(III) oxide Rh2O3 and rhodium(III) chloride RhCl3. However, macroscopic amounts of the oxide would not sublimate until 1000°C and the chloride would not until 780°C, and then only in the presence of carbon aerosol particles: these temperatures are far too high for such procedures to be used on meitnerium, as most of the current methods used for the investigation of the chemistry of superheavies do not work above 500°C.
Sources: en.wikipedia.org
I should say I wanted to write poetry in the beginning because I had fallen in love with words. The first poems I knew were nursery rhymes and before I could read them for myself I had come to love the words of them. The words alone. What the words stood for was of a very secondary importance... I fell in love, that is the only expression I can think of, at once, and am still at the mercy of words, though sometimes now, knowing a little of their behaviour very well, I think I can influence them slightly and have even learned to beat them now and then, which they appear to enjoy. I tumbled for words at once. And, when I began to read the nursery rhymes for myself, and, later, to read other verses and ballads, I knew that I had discovered the most important things, to me, that could be ever. Thomas became an accomplished writer of prose poetry, with collections such as Portrait of the Artist as a Young Dog (1940) and Quite Early One Morning (1954) showing he was capable of writing moving short stories. His first published prose work, After the Fair, appeared in The New English Weekly on 15 March 1934. Jacob Korg believes that one can classify Thomas's fiction work into two main bodies: vigorous fantasies in a poetic style and, after 1939, more straightforward narratives. Korg surmises that Thomas approached his prose writing as an alternate poetic form, which allowed him to produce complex, involuted narratives that do not allow the reader to rest.
Unlike folinic acid, it may be used in MTFHR deficiency and MTHFS deficiency: 5-MTHF is the directly usable form of folate in methoinine metabolism, in contrast to folinic acid which needs to be converted to 5-MTHF by these enzymes. Secondary CFD could be treated by non-folate drugs, depending on the precise cause. For example, serine deficiency can be helped by direct supplementation of serine and glycine: this helps with seizure control but does little for psychomotor development. Folic acid (FA), the oxidized form commonly found in diet and ordinary supplements, is not suitable for most forms of CFD and may worsen it. "Transport of folate compounds from the intestine to the brain and competitive inhibition of 5-MTHF transport by FA. Conversion of FA to 5-MTHF is limited in the intestine and is mainly handled by DHFR in the liver, although its enzymatic activity is low in humans. In contrast, folinic acid is efficiently metabolized to 5-MTHF in the intestine and liver. When an excess amount of FA is taken, it cannot be fully reduced by DHFR in the liver and unmetabolized FA appears in the plasma. Because FA has higher affinity to FR1 expressed at the choroid plexus than 5-MTHF, it can act as a competitive inhibitor against 5-MTHF transport from the plasma to the CSF. In addition, FA cannot be metabolized to 5-MTHF efficiently in the brain with extremely low DHFR activity. Thus, excess FA intake may lead to a less effective supply of 5-MTHF to the brain compared with that of folinic acid supplementation."
This measurement is made after each amplification cycle, and this is the reason why this method is called real time PCR (that is, immediate or simultaneous PCR). Quantitative PCR and DNA microarray are modern methodologies for studying gene expression. Older methods were used to measure mRNA abundance: differential display, RNase protection assay and northern blot. Northern blotting is often used to estimate the expression level of a gene by visualizing the abundance of its mRNA transcript in a sample. In this method, purified RNA is separated by agarose gel electrophoresis, transferred to a solid matrix (such as a nylon membrane), and probed with a specific DNA or RNA probe that is complementary to the gene of interest. Although this technique is still used to assess gene expression, it requires relatively large amounts of RNA and provides only qualitative or semi quantitative information of mRNA levels. Estimation errors arising from variations in the quantification method can be the result of DNA integrity, enzyme efficiency and many other factors. For this reason a number of standardization systems (often called normalization methods) have been developed. Some have been developed for quantifying total gene expression, but the most common are aimed at quantifying the specific gene being studied in relation to another gene called a normalizing gene, which is selected for its almost constant level of expression. These genes are often selected from housekeeping genes as their functions related to basic cellular survival normally imply constitutive gene expression.
Attenuated total reflectance (ATR) is one accessory of FTIR spectrophotometer to measure surface properties of solid or thin film samples rather than their bulk properties. Generally, ATR has a penetration depth of around 1 or 2 micrometers depending on sample conditions.
Sources: en.wikipedia.org
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.
Anti-doping laboratories use LC-MS/MS to detect GW501516 and its metabolites, usually in urine. The method can identify the parent compound at low concentrations. Detection windows vary with dose and individual factors.
No, cardarine has no approved medical uses in major jurisdictions. Early research explored metabolic conditions, but those programs were discontinued. It is not a registered treatment for any disease.
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.